target audience: TECH BUYER Publication date: Oct 2023 - Document type: IDC FutureScape - Doc Document number: # US51290923
IDC FutureScape: Worldwide Life Sciences 2024 Predictions
Table of Contents
-
IDC FutureScape Figure
-
Figure: IDC FutureScape: Worldwide Life Sciences 2024 Top 10 Predictions
-
-
Executive Summary
-
IDC FutureScape Predictions
-
Summary of External Drivers
-
Predictions: Impact on Technology Buyers
-
Prediction 1: By 2024, 70% of Life Sciences Organizations Will Prioritize Security-by-Design, Privacy-by-Design, and Zero Trust Initiatives to Enhance Cyber-Resilience and Build Trust, Fueled by Evolving Regulations
-
Associated Drivers
-
IT Impact
-
Patient Impact
-
Guidance
-
Prediction 2: By 2025, Transformative Patient Experiences Will Be Led by 30% of Life Sciences Firms That Used GenAI to Optimize Trial Design, Hyper-Personalize Content, and Orchestrate Empathetic Interactions
-
Associated Drivers
-
IT Impact
-
Patient Impact
-
Guidance
-
Prediction 3: By 2026, 65% of Life Sciences Companies Will Modernize Digital Infrastructure, Adopting Unified Control Planes to Optimize and Scale Intelligence-Driven Innovation and to Ensure Regulatory Compliance
-
Associated Drivers
-
IT Impact
-
Patient Impact
-
Guidance
-
Prediction 4: Pushed by Data-Driven Market Models and Patient Care Needs, 40% of Life Sciences Companies Will Adopt Integrated Solutions Combining Connected Medical Devices and Digital Health Platforms by 2026
-
Associated Drivers
-
IT Impact
-
Patient Impact
-
Guidance
-
Prediction 5: Fueled by Connected Health Devices and AI-Based Analysis Tools, the Market for Digital Biomarkers Will Double by the End of 2026, Lowering Healthcare Costs While Aiding in R&D and Outcome Measurements
-
Associated Drivers
-
IT Impact
-
Patient Impact
-
Guidance
-
Prediction 6: By 2026, the Adoption of GenAI-Based Drug Design, the Intelligent Supply Chain for Cell and Gene Therapies, and Digital Therapeutics Will Scale the Growth of Precision Therapies by 60%
-
Associated Drivers
-
IT Impact
-
Patient Impact
-
Guidance
-
Prediction 7: Despite the Decreasing Field Sales Head Count, GenAI Enhancements in Commercial Life Sciences Software Will Lead the Industry to a 40% Rise in Personalized Engagements with Healthcare Providers by 2027
-
Associated Drivers
-
IT Impact
-
Patient Impact
-
Guidance
-
Prediction 8: Evolving Home Care Initiatives and Patient Expectations Will Triple the Use of Intelligent Device–Based Drug Delivery Systems by 2027, Followed by Vectorized Antibodies and Gene Delivery Nanocarriers
-
Associated Drivers
-
IT Impact
-
Patient Impact
-
Guidance
-
Prediction 9: By 2027, One-Fourth of the Life Sciences Industry Will Supplement But Not Replace Animal Testing with Computer Simulations, Organoids, and Organ on a Chip, Prioritizing Neurological Diseases
-
Associated Drivers
-
IT Impact
-
Patient Impact
-
Guidance
-
Prediction 10: Approvals for Clinical Trials Focused on a Brain-Computer Interface Will Double by 2028, Prioritizing Neurorehabilitation While Implementing Strict Guardrails to Ensure Data Privacy and Patient Safety
-
Associated Drivers
-
IT Impact
-
Patient Impact
-
Guidance
-
-
Advice for Technology Buyers
-
External Drivers: Detail
-
AI Everywhere — Generative AI Takes the Spotlight
-
The Drive to Automate — Maximizing Efficiency and New Opportunities
-
Cybersecurity and Risk — Building Resilience Against Multiplying Threats
-
The Digital Business Imperative — Competitiveness and Outcomes
-
Dynamic Work and Skills Requirements — New Work Mode Era
-
Shifting Tech Regulatory Landscape — Navigating Risk and Opportunity
-
-
Learn More
-
Related Research
-